Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMB-100 in moderate stress urinary incontinence
NCT06247241Phase 2Withdrawn
- Sponsor
- Versameb AG
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- mRNA Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of VMB-100 in stress urinary incontinence (SUI), sponsored by Versameb AG. Primary endpoints: Adverse Events at 1 year, Serious Adverse Events at 1 year and 7 more. Planned start Sep 2025; status: withdrawn.
02
Drugs
VMB-100
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT06247241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247241.